Eli Lilly’s Trulicity (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, according to results from AWARD-10, a new Phase 3b clinical study.
These data were published online first in The Lancet Diabetes & Endocrinology. Trulicity is Eli Lilly and Company’s (NYSE: LLY) once-weekly, injectable glucagon-like peptide-1 (GLP-1) receptor agonist approved to improve blood sugar (glucose) in adults with type 2 diabetes. Trulicity should be used along with diet and exercise.
Bernhard Ludvik, M.D., associate professor of medicine, Rudolfstiftung Hospital Vienna and AWARD-10 lead author, said: “I’ve seen in my practice that even with effective oral medicines like SGLT-2 inhibitors and metformin, many adults with type 2 diabetes may still need additional therapy to maintain their blood sugar levels. The AWARD-10 results suggest that the combination of once-weekly Trulicity and an SGLT-2 inhibitor shows significant promise in helping more people with type 2 diabetes reach their treatment goals.”
“Managing type 2 diabetes with diet, exercise and oral medications may require the addition of injectable therapy for some people, given the progressive nature of the disease,” said Brad Woodward, M.D., senior medical director, Lilly Diabetes. “AWARD-10 showed that Trulicity, when used in combination with an SGLT-2 inhibitor and metformin, may be effective and well tolerated in people with type 2 diabetes.”